CervoMed Inc. — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Diffusion Pharmaceuticals Inc. (DFFN)
CIK: 0001053691
Period of Report: 2021-07-01

Reporting Person: LANCHONEY DIANA M (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-01	Stock Option (Right to Buy)	$0.72	A	83300	Acquired	2031-07-01	Common Stock (83300)	Direct
2021-07-01	Stock Option (Right to Buy)	$0.72	A	83300	Acquired	2031-07-01	Common Stock (83300)	Direct
2021-07-01	Restricted Stock Unit	$	A	69400	Acquired		Common Stock (69400)	Direct

Footnotes

F1: The shares underlying the options will vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 12-month period beginning July 1, 2021.

F2: The shares underlying the options will vest in 18 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over an 18-month period beginning July 1, 2021.

F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4: The shares underlying the restricted stock units will vest in 6 equal (or as nearly equal as possible) tri-monthly installments on the last calendar day of every third month over an 18-month period beginning on January 1, 2023.